Objectives Given the rapidly evolving therapeutic landscape for type 2 diabetes (T2D) and chronic kidney disease (CKD), this study aimed to characterise the clinical profiles and real-world outcomes ...
3d
Oracle May Not Be Able to Build Its Michigan Data Center After All. Should You Sell ORCL Stock Now?
Oracle still looks more like a hold than a sell, with fast‑growing cloud and AI revenue and a Street “Moderate Buy” rating with about 70% implied upside.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback